Nivilumab and ibulimab side effects
Reading File
Nivolumab is a PD-1 checkpoint inhibitor and ipilimumab is a CTLA-4 checkpoint inhibitor - both are immunotherapy agents used in cancer treatment. Their side effects are primarily immune-related adverse events (irAEs). Let me search the medical library and current literature simultaneously.
Searching sources...
Finding Sources
Finding Sources
Searching PubMed
nivolumab ipilimumab immune-related adverse events
Now let me read the most relevant textbook sections for a detailed breakdown of irAEs:
Reading File
Reading File
Reading File
Now let me get the detailed side effect table and the Andrews/dermatology section for skin reactions:
Reading File
Reading File
I now have comprehensive information from multiple textbooks. Here is the full detailed answer:
Nivolumab and Ipilimumab - Side Effects
Note on spelling: You likely mean nivolumab (Opdivo) and ipilimumab (Yervoy). These are two immune checkpoint inhibitors commonly used together or as monotherapy in cancers such as melanoma, NSCLC, and renal cell carcinoma.
Mechanisms (Why They Cause These Effects)
- Nivolumab blocks PD-1 (programmed cell death protein 1), an inhibitory receptor on T cells - releasing the "brake" on T cell activity against tumors.
- Ipilimumab blocks CTLA-4, a different inhibitory receptor that competes with CD28 to downregulate early T cell activation.
Both mechanisms remove natural immune checkpoints, so activated T cells can attack normal tissues - causing immune-related adverse events (irAEs).
Side Effects by System
Dermatological (Most Common)
| Effect | Details |
|---|---|
| Nonspecific rash (maculopapular) | 15-29% of patients; most common overall |
| Pruritus | ~12% |
| Vitiligo / leukoderma | 7-9%; notably correlated with better tumor response |
| Lichenoid reactions | Skin and oral (lichenoid mucositis) - both common |
| Alopecia | Including alopecia areata/universalis pattern (unlike classic chemo hair loss) |
| Bullous pemphigoid-like eruption | With anti-BP180 antibodies; rare but documented |
| Rare reactions | Vasculitis, granulomatous eruptions (sarcoidosis, granuloma annulare), panniculitis, lupus-like reactions, SJS/TEN, eruptive keratoacanthomas |
(Andrews' Diseases of the Skin; Dermatology 2-Volume Set 5e)
Gastrointestinal
- Colitis - one of the most significant irAEs, especially with ipilimumab
- Diarrhea, enterocolitis (can be severe; may require fluid/electrolyte repletion)
- Immune-mediated hepatitis (elevated transaminases; also seen with nivolumab)
Endocrine
- Thyroiditis (hypo- or hyperthyroidism)
- Hypophysitis (pituitary inflammation - can cause panhypopituitarism, very characteristic of ipilimumab)
- Adrenal insufficiency (can be life-threatening if missed)
Pulmonary
- Pneumonitis - can require oxygen therapy or mechanical ventilation in severe cases
Cardiac
- Myocarditis - rare but potentially fatal; presents with new dyspnea, arrhythmias, or pulmonary edema
Neurological
- Neuropathy, encephalopathy, cranial nerve palsies
- Recent systematic review (2024) documented cranial nerve involvement in 136 patients on checkpoint inhibitors
Renal
- Nephritis (interstitial nephritis most common)
Nivolumab vs. Ipilimumab: Comparative Toxicity
| Feature | Ipilimumab (CTLA-4) | Nivolumab (PD-1) |
|---|---|---|
| Grade 3-4 irAE rate (monotherapy) | Higher (~27% or more) | Lower (~16%) |
| Colitis / GI toxicity | More common, more severe | Less common |
| Hypophysitis | More frequent | Less frequent |
| Dermatologic | Both common | Both common |
| Overall tolerability | Less well tolerated | Better tolerated |
Combination nivolumab + ipilimumab: Response rates jump (~61% vs 11% for ipilimumab alone) but grade 3-4 side effects increase significantly compared to either agent alone. Newer dosing regimens aim to reduce toxicity while maintaining efficacy. - Dermatology 2-Volume Set 5e
In head and neck cancer, nivolumab had 14.4% grade 3-4 events vs. 45.9% with standard chemotherapy. - Cummings Otolaryngology
Onset and Timing
irAEs typically manifest weeks to months after starting therapy, not immediately. This delay can make attribution challenging. - Miller's Anesthesia, 10e
Management of irAEs
- Mild (Grade 1): Continue therapy with monitoring
- Moderate-Severe (Grade 2-3): Interrupt checkpoint inhibitor; start systemic corticosteroids (mainstay of treatment)
- Refractory / Grade 4: Add TNF-alpha antagonists (e.g., infliximab for colitis); discontinue drug
- ICU-level irAEs: Severe pneumonitis (ventilatory support), myocarditis (inotropes, antiarrhythmics), hepatic failure, severe enterocolitis (IV fluids/electrolytes)
- Opportunistic infections are a real risk in patients on prolonged immunosuppression for irAE management
(Miller's Anesthesia, 10e; Dermatology 2-Volume Set 5e)
Key Takeaways
- irAEs can affect virtually any organ - think "immune attack on self"
- Ipilimumab (CTLA-4) generally causes more severe toxicity than nivolumab (PD-1)
- Combining both dramatically raises efficacy AND toxicity
- Paradoxically, some irAEs (especially vitiligo/leukoderma) correlate with better treatment response
- Management is primarily immunosuppression with corticosteroids
When endocrine sideffects start after giving drugs
Endocrine irAEs from nivolumab and ipilimumab typically appear later than skin/GI side effects - usually after 6-12 weeks, sometimes months into therapy. Let me get precise timing data from the textbooks.
Searching sources...
Finding Sources
Finding Sources
Searching PubMed
immune checkpoint inhibitor endocrine adverse events timing onset
Good lead from Tintinalli's. Let me read that section and also get the detailed endocrine irAE timing from other sources:
Reading File
Finding Sources
Reading Article
PMID: 35912205
Good data found. Let me read more of the Tintinalli section for the specific endocrine timing details:
Reading File
Finding Sources
Let me get the full Tintinalli paragraph that was cut off about hypophysitis and thyroid timing:
Reading File
Finding Sources
Now let me get the web search for the well-established irAE timeline data (the classic "temporal sequence" from ASCO/ESMO guidelines):
Searching the Web
nivolumab ipilimumab endocrine irAE onset timing weeks hypophysitis thyroiditis adrenal
Excellent - I now have very precise, well-sourced timing data. Here is the full answer:
Endocrine Side Effects: When Do They Start?
Endocrine irAEs are typically later-onset compared to skin and GI side effects. The timing varies by the specific gland affected and which drug is used.
General Timeline of All irAEs (for Context)
irAEs follow a rough temporal pattern after starting therapy:
| Organ System | Typical Onset |
|---|---|
| Skin (rash, pruritus) | Earliest - weeks 1-4 |
| GI (colitis, diarrhea) | ~6 weeks after start |
| Hepatitis | ~6-12 weeks |
| Endocrine | Later - typically 6 weeks to 6 months |
| Neurological / renal | Variable, can be late |
(Tintinalli's Emergency Medicine; Miller's Anesthesia, 10e)
The general principle: endocrine side effects tend to appear later than skin/GI effects, but can occur at any point - even after treatment stops.
Endocrine irAEs: Specific Onset Timing
1. Thyroiditis (Hypothyroidism / Transient Thyrotoxicosis)
| Regimen | Thyrotoxic Phase Onset | Hypothyroid Phase Onset |
|---|---|---|
| Nivolumab alone | ~6 weeks | ~17 weeks |
| Ipilimumab + Nivolumab (combo) | ~2 weeks (faster!) | ~10 weeks |
| Pembrolizumab | ~5 weeks | Follows thyrotoxic phase |
Key point: combination therapy causes faster and more abrupt thyroid dysfunction. Most patients who develop thyrotoxicosis go on to become permanently hypothyroid requiring levothyroxine. - PMC thyroiditis study
2. Hypophysitis (Pituitary Inflammation)
| Regimen | Median Time to Onset |
|---|---|
| Ipilimumab alone | ~9-12 weeks (approximately 83 days) |
| Ipilimumab + Nivolumab | ~83 days (~12 weeks) |
| Nivolumab / PD-1 alone | Much later - ~26 weeks |
- Ipilimumab-induced hypophysitis is far more common and earlier than PD-1-induced hypophysitis
- It causes secondary adrenal insufficiency, central hypothyroidism, and hypogonadism
- Symptoms are often non-specific (headache, fatigue, visual changes) - frequently missed until adrenal crisis
3. Adrenal Insufficiency
- Mostly occurs secondary to hypophysitis (not primary adrenal failure)
- Onset mirrors hypophysitis timing: ~9-12 weeks with ipilimumab, later with PD-1 inhibitors
- Underdiagnosed - most cases only identified after symptom onset or acute crisis in emergency settings. Routine ACTH/cortisol screening is rarely performed despite guidelines recommending it.
- Life-threatening if missed; requires hydrocortisone replacement
4. ICI-Induced Diabetes Mellitus (Fulminant Type 1-like)
- Less common, more associated with PD-1 inhibitors (nivolumab, pembrolizumab)
- Can occur any time, often weeks to months into therapy
- Presents rapidly (sometimes as DKA) - faster than classic autoimmune T1DM
- Median time to onset: 1.4-4.9 months with PD-1 inhibitors
5. Overall Endocrine irAE Summary Timing
| Drug | Median time to moderate-severe endocrinopathy |
|---|---|
| Ipilimumab (CTLA-4) | 1.75-5 months |
| Nivolumab/PD-1 inhibitors | 1.4-4.9 months |
Why Endocrine Effects Appear Later
- CTLA-4 is expressed on pituitary cells - ipilimumab creates a direct pituitary-targeted immune attack
- PD-L1 is expressed on thyroid, pituitary, and pancreas - PD-1 blockers can attack these over time
- Endocrine organs tolerate partial immune damage longer before becoming symptomatic (silent until >50% gland function is lost for some)
- Immune activation is a gradual process - cumulative drug doses drive later toxicities
Clinical Bottom Line
- Thyroid: can start as early as 2 weeks (combo therapy) to 6 weeks (monotherapy) - monitor TSH/FT4 at each cycle
- Pituitary/Adrenal: typically 9-12 weeks with ipilimumab; up to 6 months with PD-1 alone - check morning cortisol + ACTH periodically
- Diabetes: weeks to months - check fasting glucose/HbA1c regularly, especially with PD-1 agents
- Endocrine irAEs can be permanent (especially hypothyroidism, adrenal insufficiency, diabetes) even after stopping the drug - unlike dermatologic/GI irAEs which often resolve
- Any patient on these drugs presenting with fatigue, headache, nausea, or weight change should prompt endocrine screening
This is a shared conversation. Sign in to Orris to start your own chat.